Latest News:

Tufts CSDD Demonstrates Multi-Million-Dollar Benefits of Translational Pharmaceutics®

Assessing the Financial Impact of Translational Pharmaceutics®

A white paper by Tufts CSDD comparing the savings and financial benefits for drug developers that use Translational Pharmaceutics®

Unlock the multi-million dollar benefits of Translational Pharmaceutics®, demonstrated in the Tufts CSDD study

Discover the time savings and financial benefits for drug developers that use Translational Pharmaceutics®, versus traditional multi-vendor formulation, manufacturing and clinical testing approaches.

Download the white paper today!

Would you like to receive further scientific content including case studies, whitepapers and seminar and webinar invitations?
You can find out how we handle your personal information in our privacy policy here.

What can I learn?

Discover how to benefit from:

  • A faster approach to drug development and accelerated time to market
  • Average timeline savings of >12 months
  • R&D spend reduced by $9.5 million for each month of time saved
  • Total financial gains per drug approved >$100 million
  • Formulations selected using clinical data ensuring greater chances of success
  • An integrated development model and simplified supply chain

About Translational Pharmaceutics®

Translational Pharmaceutics accelerates drug development by integrating formulation development, real-time manufacturing and clinical testing. Over the past decade it has been used widely by pharmaceutical and biotech companies on >400 programs to advance molecules across the full development cycle from first-in-human trials to market (FIH) Key applications within development process include:

  • Transitioning molecules from first-in-human (FIH) to proof-of-concept (POC)
  • Development and optimization of clinical formulations

About the Tufts CSDD study

The Tufts Center for the Study of Drug Development (CSDD) compared the cycle times of traditional drug development programs to Translational Pharmaceutics programs and their derivative effects on development economics. These data were incorporated in a drug development model and the financial benefits were quantified on industry R&D costs and returns. The model assessed several different project types and the top line results included mean financial benefits exceeding $100 million and mean timeline savings of >12 months.

Learn more about Translational Pharmaceutics

Latest news and events

Ready to accelerate your drug development?

Discover Translational Pharmaceutics

Ask us a question

We use cookies to help us to improve our site and enables us to the best possible service and customer experience. By clicking accept you are agreeing to let us share your data with select third parties for analytics and marketing purposes.